Innovation for Health — The Fourth Hongqiao International Health Technology Innovation Forum Held in Shanghai
The forum brought together leaders and expert representatives from the government, industry, clinical and scientific research institutions and investment community. In this forum, global cutting-edge health science and technology achievements and development trends were focused on, in-depth exchanges and discussions were conducted on hot topics such as local pharmaceutical innovation and internationalization in China, and the path to healthy China was jointly explored, so as to contribute Chinese wisdom to the global health.
![](/en/news/20211201164919_4316.jpg)
Sharing Policy Opportunities
Domestic Pharmaceutical Innovation Enters the Fast Track
The year 2021 marks the beginning of the 14th Five-Year Plan. In this year, the construction of "Healthy China" has risen to the national strategic level. As one of the key industries supported and developed by China, the biomedical industry has ushered in significant development opportunities and challenges.
![](/en/news/20211201164946_4726.jpg)
Global Cooperation Promotes Spread of "Chinese Innovation" to the World
There is still a long way to go in the prevention and control of epidemic. Global medical science and technology has witnessed accelerated innovation and the importance of science and technology in the fight against the epidemic has become more and more prominent. Gao Fu, Academician of Chinese Academy of Sciences and Director of the Chinese Center for Disease Control and Prevention, said in his video speech that when community transmission caused by imported cases becomes normalized, the key to more scientific and accurate suppression is strong grassroots public health prevention and control. He called for vaccine sharing globally to unite in the fight against the epidemic; and also called for focusing on investment in science, especially in the microbiological field.
Chen Qiyu said that after the tempering of the epidemic, we have entered the post-epidemic era; from clinical R&D, review and approval, manufacturing to transportation and supply, the global medical market is forming a new collaboration mechanism, and China will also become an important participant in the whole chain of global innovative drug R&D. "The CIIE brings together global innovative technologies and is an important platform for exchanges and collaboration. This is the fourth time that Fosun has participated in the exhibition this year and Fosun has benefited a lot from the exhibition. I hope that Chinese enterprises will continue to improve their level of innovation in such exchanges, achieve more high-level global collaborations, and jointly contribute to the development of global biomedicine. "
![](/en/news/20211201170430_4599.jpg)
Aligning with International Innovation
Contributing "Chinese Wisdom" to Global Health
Under the intertwining of the century-old changes and the epidemic of the century, how to integrate Chinese wisdom and innovation with global innovation so as to contribute to global health has become an important issue. At the meeting, under the presidency of Feng Lan, Secretary-General of the China Pharmaceutical Innovation and Research Development Association, Wu Fan, Vice President of Shanghai Medical College of Fudan University and President of Shanghai Institute of Major Infectious Diseases and Biosafety, Shen Wenjiang, Lifelong Honorary Professor and Chief Physician in Department of Radiation Oncology of Peking University Health Science Center and Chairman of the Radiation Therapy Branch of Standardization Administration of the PRC, Wu Xiaobin, President and Chief Operating Officer of BeiGene, He Jing, Senior Vice President of Global Cancer R&D and President of Global R&D China Center of AstraZeneca, Liang Jin, Managing Director and Head of Pharmaceutical and Medical Industry Group of China International Capital Corporation Limited (CICC), Wu Yifang, Chairman and CEO of Fosun Pharma, and other experts in the fields of industry, university, research and investment discussed the normalization of epidemic prevention and control and high-quality international innovation and cooperation.
The speed of vaccine R&D in China reflects the speed of China's pharmaceutical innovation. With the support of policies, new R&D enterprises are constantly emerging, forming an upsurge of innovation in China's pharmaceutical industry. Some experts said that for Chinese pharmaceutical enterprises, active promotion by the government and building up R&D, technology and talent reserves by enterprises are required for innovation.
At the same time, the epidemic has highlighted the importance of international cooperation. Under the call of building a global community of health for all, China promotes the high-level development of pharmaceutical innovation, and also lets China's pharmaceutical innovation and the world share opportunities together. The participants also expected that China's originality will promote the advancement of world medicine, and greatly improve the accessibility and affordability of medicine to patients worldwide.
On the same day, under the guidance of the relevant departments and bureaus of the National Health Commission of the People's Republic of China, the IHECC and Fosun Pharma joined hands to launch the signing ceremony of the "Health Demonstration Project for Rural Revitalization". In the future, the two sides will actively explore public welfare paths, create a "health demonstration project for rural revitalization", take the capacity building of rural doctors and the improvement of grassroots medical service capabilities as the starting point, carry out work based on the practical needs of key groups such as the elderly and children in rural areas, and explore experience that can be replicated and promoted nationwide.